Federal regulators say they are working with all six manufacturers of estradiol transdermal patches to increase supply, after months of reports from women who cannot reliably fill a prescription that millions of Americans have come to depend on for menopause symptoms.
The Food and Drug Administration issued the update on September 3. It acknowledged reports of patients having difficulty readily accessing their usual patch because of increased demand and said availability of certain products or brands varies by pharmacy and location, while stating that estradiol patches remain available. The agency also said the supply of FDA-approved estradiol patches has nearly doubled over the past year, and that manufacturers are increasing production, adding shifts, expanding capacity, increasing batch sizes, adding specialized equipment and manufacturing lines, and prioritizing patch production.
What the agency did not do is add estradiol patches to its formal drug shortage list. That gap between the official designation and the experience at the pharmacy counter is the center of this story.
The Designation Fight Behind the Empty Shelf
A formal shortage listing is not a symbolic label. It can unlock regulatory flexibility, signal suppliers and prescribers, and direct agency resources toward addressing underlying causes.
The American Society of Health-System Pharmacists, which collects reports from pharmacists, providers and patients, lists more than a dozen estradiol patch products on its active drug shortage list. FDA's own shortage database does not carry the same listing. That divergence is what has driven clinician frustration.
Menopause clinics have been describing the same pattern since winter. Dr. Rajita Patil, director of UCLA Health's Comprehensive Menopause Program, told NBC News that demand has risen sharply over three or four years and added, "I don't think that the supply chain was ready for that."
Dr. Suzanne Hackenmiller, an obstetrician-gynecologist in Arizona, has started a petition asking FDA to formally declare a shortage. She told CBS News that a declaration could give current manufacturers an incentive to ramp up production and could encourage other companies to enter the market, and described the drugs as "medically necessary medications that are preventing disease in women after menopause."
A group of Democratic members of the U.S. House has also urged the agency to add estradiol patches to the federal shortage database. In a letter, the lawmakers argued that FDA relies on historical demand data to judge whether manufacturers are keeping pace, and that such data may lag when demand rises as quickly as it has. CBS reported that the agency did not respond to its request for comment before posting the September update.
FDA, for its part, framed rising demand as "an important development for women's health" and said it is working closely with manufacturers to keep supply moving. Both descriptions can hold at once. A product can be manufactured at capacity and still be unavailable at a given pharmacy on a given day.
The Policy Change That Reshaped Demand
The surge traces to a specific regulatory decision. In November 2025, FDA asked manufacturers to change labeling to remove boxed warnings on menopausal hormone therapy products that described a probable risk of breast cancer, cardiovascular disease and probable dementia. The agency said the change gave women and clinicians updated information for individualized discussions about benefits and risks. The labeling action followed two decades in which the warning discouraged both prescribing and use.
Prescribing rose quickly afterward. Estrogen patch prescriptions increased from about 594,000 in June 2024 to 1.6 million in May 2026, according to nationwide data from the health technology company HealthVerity cited by CBS News. Separate analysis by Epic Research, which examines electronic health records, found hormone therapy prescriptions for women aged 50 to 65 up 86 percent since 2021.
Supply did not move at the same speed, and the reason is manufacturing physics rather than reluctance. FDA notes that transdermal patches require specialized equipment and processes, so larger manufacturing expansions take time even when a company commits to them.
The Households Absorbing the Gap
The burden shows up in ordinary logistics. Diane Harris, a Los Angeles mother of three who uses a twice-weekly patch, told CBS News she called every pharmacy she could think of, began using her patches less often when she could not find a consistent supply, and eventually filled the prescription at a pharmacy more than 25 miles from home.
Cost is a second layer. Hackenmiller said some patients who normally receive a 90-day supply are being given 30-day supplies because pharmacies cannot fill the full prescription, which can mean paying a copay three times instead of once.
Switching products is not always simple either. Patil told NBC News that some women become more symptomatic on weekly patches than on twice-weekly ones, and that even moving between brands of the same product can cause problems because the non-drug components differ. Clinicians quoted by NBC said the shortages appear to be hitting twice-weekly patches hardest.
The Steps That Actually Help Right Now
FDA's guidance is direct: do not stop or change hormone therapy without talking to a health care provider. That is worth stating plainly, because abrupt discontinuation returns symptoms and is not a safe workaround for an out-of-stock notice.
The agency asks patients to contact their pharmacist first, since a pharmacist can check availability and may be able to locate another FDA-approved estradiol patch that can be substituted when appropriate. It also asks patients to talk with their prescriber about whether another estradiol product is suitable, and to check back with the pharmacy as manufacturers release more supply.
Other delivery routes exist. The American College of Obstetricians and Gynecologists describes estrogen therapy as the most effective treatment for hot flashes and night sweats, and notes that it also comes as pills, gels, injections and vaginal inserts. Clinicians interviewed by NBC News said patches are often preferred over pills because they carry a lower risk of blood clots, which is why a switch is a prescriber's decision rather than a substitution a patient should make alone.
FDA said it will continue monitoring supply and expediting review of submissions related to increasing production. The next concrete developments to watch are whether the agency adds estradiol patches to the shortage database and whether ASHP's listings begin to clear. Neither has a published timeline.
Key Questions Answered
What did FDA announce? The agency said it is aware of patients having difficulty accessing their usual estradiol patch and is working with all six manufacturers to increase supply.
Are estradiol patches officially in shortage? No. FDA has not added them to its drug shortage database, although the American Society of Health-System Pharmacists lists more than a dozen patch products on its own shortage list.
Why does the designation matter? Supporters say a formal listing could unlock regulatory flexibility and give manufacturers an incentive to expand production. Without it, the problem is managed pharmacy by pharmacy.
What caused the surge in demand? FDA asked manufacturers to remove the boxed warning from menopausal hormone therapy labeling in November 2025, and prescribing rose sharply afterward.
Should patients stop their hormone therapy? No. FDA advises not stopping or changing medication without speaking with a health care provider.
What alternatives exist? A different manufacturer's patch, or other estrogen products including pills, gels, injections, and vaginal inserts. A clinician decides what is appropriate.
Could switching products cause problems? Yes. Clinicians report that some patients do worse on weekly patches than twice-weekly ones, and pharmacies filling shorter supplies can raise a patient's total copay costs.
